AustralieFrV1, PascalFrancis, Corpus, bibRecord, 003D00

Contemporary clinical profile and outcome of prosthetic valve endocarditis

Identifieur interne : 003D00 ( PascalFrancis/Corpus ); précédent : 003C99; suivant : 003D01

Contemporary clinical profile and outcome of prosthetic valve endocarditis

Auteurs : Andrew Wang ; Eugene Athan ; Paul A. Pappas ; Vance G. Jr Fowler ; Lars Olaison ; Carlos Pare ; Benito Almirante ; Patricia Munoz ; Marco Rizzi ; Christoph Naber ; Mateja Logar ; Pierre Tattevin ; Diana L. Iarussi ; Christine Selton-Suty ; Sandra Braun Jones ; José Casabe ; Arthur Morris ; Ralph Corey ; Christopher H. Cabell

Source :

JAMA, the journal of the American Medical Association [ 0098-7484 ] ; 2007.

RBID : Pascal:07-0191068

Descripteurs français

Pascal (Inist)
- Prothèse, Symptomatologie, Evolution, Endocardite, Pronostic, Valvule cardiaque, Médecine.

English descriptors

KwdEn :
- Endocarditis, Evolution, Heart valve, Medicine, Prognosis, Prosthesis, Symptomatology.

Abstract

Context Prosthetic valve endocarditis (PVE) is associated with significant mortality and morbidity. The contemporary clinical profile and outcome of PVE are not well defined. Objectives To describe the prevalence, clinical characteristics, and outcome of PVE, with attention to health care-associated infection, and to determine prognostic factors associated with in-hospital mortality. Design, Setting, and Participants Prospective, observational cohort study conducted at 61 medical centers in 28 countries, including 556 patients with definite PVE as defined by Duke University diagnostic criteria who were enrolled in the International Collaboration on Endocarditis-Prospective Cohort Study from June 2000 to August 2005. Main Outcome Measure In-hospital mortality. Results Definite PVE was present in 556 (20.1 %) of 2670 patients with infective endocarditis. Staphylococcus aureus was the most common causative organism (128 patients [23.0%]), followed by coagulase-negative staphylococci (94 patients [16.9%]). Health care-associated PVE was present in 203 (36.5%) of the overall cohort. Seventy-one percent of health care-associated PVE occurred within the first year of valve implantation, and the majority of cases were diagnosed after the early (60-day) period. Surgery was performed in 272 (48.9%) patients during the index hospitalization. In-hospital death occurred in 127 (22.8%) patients and was predicted by older age, health care-associated infection (62/203 [30.5%]; adjusted odds ratio [OR], 1.62; 95% confidence interval [Cl], 1.08-2.44; P=.02), S aureus infection (44/128 [34.4%]; adjusted OR, 1.73; 95% Cl, 1.01-2.95; P=.05), and complications of PVE, including heart failure (60/183 [32.8%]; adjusted OR, 2.33; 95% Cl, 1.62-3.34; P<.001), stroke (34/101 [33.7%]; adjusted OR, 2.25; 95% Cl, 1.25-4.03; P=.007), intracardiac abscess (47/144 [32.6%]; adjusted OR, 1.86; 95% Cl, 1.10-3.15; P=.02), and persistent bacteremia (27/49 [55.1 %]; adjusted OR, 4.29; 95% Cl, 1.99-9.22; P<.001). Conclusions Prosthetic valve endocarditis accounts for a high percentage of all cases of infective endocarditis in many regions of the world. Staphylococcus aureus is now the leading cause of PVE. Health care-associated infection significantly influences the clinical characteristics and outcome of PVE. Complications of PVE strongly predict in-hospital mortality, which remains high despite prompt diagnosis and the frequent use of surgical intervention.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0098-7484`
A03		`1`		`@0 JAMA j. Am. Med. Assoc.`
A05				`@2 297`
A06				`@2 12`
A08	`01`	`1`	`ENG`	`@1 Contemporary clinical profile and outcome of prosthetic valve endocarditis`
A11	`01`	`1`		`@1 WANG (Andrew)`
A11	`02`	`1`		`@1 ATHAN (Eugene)`
A11	`03`	`1`		`@1 PAPPAS (Paul A.)`
A11	`04`	`1`		`@1 FOWLER (Vance G. JR)`
A11	`05`	`1`		`@1 OLAISON (Lars)`
A11	`06`	`1`		`@1 PARE (Carlos)`
A11	`07`	`1`		`@1 ALMIRANTE (Benito)`
A11	`08`	`1`		`@1 MUNOZ (Patricia)`
A11	`09`	`1`		`@1 RIZZI (Marco)`
A11	`10`	`1`		`@1 NABER (Christoph)`
A11	`11`	`1`		`@1 LOGAR (Mateja)`
A11	`12`	`1`		`@1 TATTEVIN (Pierre)`
A11	`13`	`1`		`@1 IARUSSI (Diana L.)`
A11	`14`	`1`		`@1 SELTON-SUTY (Christine)`
A11	`15`	`1`		`@1 BRAUN JONES (Sandra)`
A11	`16`	`1`		`@1 CASABE (José)`
A11	`17`	`1`		`@1 MORRIS (Arthur)`
A11	`18`	`1`		`@1 COREY (Ralph)`
A11	`19`	`1`		`@1 CABELL (Christopher H.)`
A14	`01`			`@1 Department of Medicine, Duke University Medical Center @2 Durham, NC @3 USA @Z 1 aut. @Z 4 aut. @Z 18 aut. @Z 19 aut.`
A14	`02`			`@1 Department of Infectious Disease, The Geelong Hospital at the University of Melbourne @2 Melbourne @3 AUS @Z 2 aut.`
A14	`03`			`@1 Outcomes Research and Assessment Group, Duke Clinical Research Institute @2 Durham, NC @3 USA @Z 3 aut.`
A14	`04`			`@1 Department of Infectious Disease, Sahlgrenska Universitetssjukhuset/ Ostra @2 Göteborg @3 SWE @Z 5 aut.`
A14	`05`			`@1 Department of Cardiology, University of Barcelona @2 Barcelona @3 ESP @Z 6 aut.`
A14	`06`			`@1 Infectious Diseases Department, Hospital Universitari Vall d'Hebron @2 Barcelona @3 ESP @Z 7 aut.`
A14	`07`			`@1 Department of Infectious Disease, Hospital General Universitario Gregorio Maranon @2 Barcelona @3 ESP @Z 8 aut.`
A14	`08`			`@1 Department of Infectious Disease, Ospedali Riuniti @2 Bergamo @3 ITA @Z 9 aut.`
A14	`09`			`@1 Cardiology Clinic, University Essen @2 Essen @3 DEU @Z 10 aut.`
A14	`10`			`@1 Department of Infectious Disease, Medical Center Ljublijana @2 Ljublijana @3 SVN @Z 11 aut.`
A14	`11`			`@1 Department of Infec tious Disease, Pontchaillou University @2 Rennes @3 FRA @Z 12 aut.`
A14	`12`			`@1 Department of Cardiology, II Universita di Napoli @2 Naples @3 ITA @Z 13 aut.`
A14	`13`			`@1 Cardiology Service, CHU Nancy-Brabois @2 Nancy @3 FRA @Z 14 aut.`
A14	`14`			`@1 Laboratorio de Tecnicas No Invasivas, Hospital Clinico Pont Universidad Catolica de Chile @2 Santiago @3 CHL @Z 15 aut.`
A14	`15`			`@1 Department of Cardiology, Institute de Cardiologia y Cirugia Cardiovascular, Fundacion Favaloro @2 Buenos Aires @3 ARG @Z 16 aut.`
A14	`16`			`@1 Diagnostic Medlab, Auckland City Hospital @2 Auckland @3 NZL @Z 17 aut.`
A20				`@1 1354-1361`
A21				`@1 2007`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 5051 @5 354000145706680070`
A44				`@0 0000 @1 © 2007 INIST-CNRS. All rights reserved.`
A45				`@0 41 ref.`
A47	`01`	`1`		`@0 07-0191068`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 JAMA, the journal of the American Medical Association`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Context Prosthetic valve endocarditis (PVE) is associated with significant mortality and morbidity. The contemporary clinical profile and outcome of PVE are not well defined. Objectives To describe the prevalence, clinical characteristics, and outcome of PVE, with attention to health care-associated infection, and to determine prognostic factors associated with in-hospital mortality. Design, Setting, and Participants Prospective, observational cohort study conducted at 61 medical centers in 28 countries, including 556 patients with definite PVE as defined by Duke University diagnostic criteria who were enrolled in the International Collaboration on Endocarditis-Prospective Cohort Study from June 2000 to August 2005. Main Outcome Measure In-hospital mortality. Results Definite PVE was present in 556 (20.1 %) of 2670 patients with infective endocarditis. Staphylococcus aureus was the most common causative organism (128 patients [23.0%]), followed by coagulase-negative staphylococci (94 patients [16.9%]). Health care-associated PVE was present in 203 (36.5%) of the overall cohort. Seventy-one percent of health care-associated PVE occurred within the first year of valve implantation, and the majority of cases were diagnosed after the early (60-day) period. Surgery was performed in 272 (48.9%) patients during the index hospitalization. In-hospital death occurred in 127 (22.8%) patients and was predicted by older age, health care-associated infection (62/203 [30.5%]; adjusted odds ratio [OR], 1.62; 95% confidence interval [Cl], 1.08-2.44; P=.02), S aureus infection (44/128 [34.4%]; adjusted OR, 1.73; 95% Cl, 1.01-2.95; P=.05), and complications of PVE, including heart failure (60/183 [32.8%]; adjusted OR, 2.33; 95% Cl, 1.62-3.34; P<.001), stroke (34/101 [33.7%]; adjusted OR, 2.25; 95% Cl, 1.25-4.03; P=.007), intracardiac abscess (47/144 [32.6%]; adjusted OR, 1.86; 95% Cl, 1.10-3.15; P=.02), and persistent bacteremia (27/49 [55.1 %]; adjusted OR, 4.29; 95% Cl, 1.99-9.22; P<.001). Conclusions Prosthetic valve endocarditis accounts for a high percentage of all cases of infective endocarditis in many regions of the world. Staphylococcus aureus is now the leading cause of PVE. Health care-associated infection significantly influences the clinical characteristics and outcome of PVE. Complications of PVE strongly predict in-hospital mortality, which remains high despite prompt diagnosis and the frequent use of surgical intervention.
C02	`01`	`X`		`@0 002B01`
C02	`02`	`X`		`@0 002B25I`
C02	`03`	`X`		`@0 002B12A04`
C03	`01`	`X`	`FRE`	`@0 Prothèse @5 01`
C03	`01`	`X`	`ENG`	`@0 Prosthesis @5 01`
C03	`01`	`X`	`SPA`	`@0 Prótesis @5 01`
C03	`02`	`X`	`FRE`	`@0 Symptomatologie @5 02`
C03	`02`	`X`	`ENG`	`@0 Symptomatology @5 02`
C03	`02`	`X`	`SPA`	`@0 Sintomatología @5 02`
C03	`03`	`X`	`FRE`	`@0 Evolution @5 03`
C03	`03`	`X`	`ENG`	`@0 Evolution @5 03`
C03	`03`	`X`	`SPA`	`@0 Evolución @5 03`
C03	`04`	`X`	`FRE`	`@0 Endocardite @5 04`
C03	`04`	`X`	`ENG`	`@0 Endocarditis @5 04`
C03	`04`	`X`	`SPA`	`@0 Endocarditis @5 04`
C03	`05`	`X`	`FRE`	`@0 Pronostic @5 05`
C03	`05`	`X`	`ENG`	`@0 Prognosis @5 05`
C03	`05`	`X`	`SPA`	`@0 Pronóstico @5 05`
C03	`06`	`X`	`FRE`	`@0 Valvule cardiaque @5 06`
C03	`06`	`X`	`ENG`	`@0 Heart valve @5 06`
C03	`06`	`X`	`SPA`	`@0 Válvula cardíaca @5 06`
C03	`07`	`X`	`FRE`	`@0 Médecine @5 08`
C03	`07`	`X`	`ENG`	`@0 Medicine @5 08`
C03	`07`	`X`	`SPA`	`@0 Medicina @5 08`
C07	`01`	`X`	`FRE`	`@0 Appareil circulatoire pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Cardiovascular disease @5 37`
C07	`01`	`X`	`SPA`	`@0 Aparato circulatorio patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Cardiopathie @5 38`
C07	`02`	`X`	`ENG`	`@0 Heart disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Cardiopatía @5 38`
C07	`03`	`X`	`FRE`	`@0 Endocarde pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Endocardial disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Endocardio patología @5 39`
N21				`@1 128`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 07-0191068 INIST
ET :	Contemporary clinical profile and outcome of prosthetic valve endocarditis
AU :	WANG (Andrew); ATHAN (Eugene); PAPPAS (Paul A.); FOWLER (Vance G. JR); OLAISON (Lars); PARE (Carlos); ALMIRANTE (Benito); MUNOZ (Patricia); RIZZI (Marco); NABER (Christoph); LOGAR (Mateja); TATTEVIN (Pierre); IARUSSI (Diana L.); SELTON-SUTY (Christine); BRAUN JONES (Sandra); CASABE (José); MORRIS (Arthur); COREY (Ralph); CABELL (Christopher H.)
AF :	Department of Medicine, Duke University Medical Center/Durham, NC/Etats-Unis (1 aut., 4 aut., 18 aut., 19 aut.); Department of Infectious Disease, The Geelong Hospital at the University of Melbourne/Melbourne/Australie (2 aut.); Outcomes Research and Assessment Group, Duke Clinical Research Institute/Durham, NC/Etats-Unis (3 aut.); Department of Infectious Disease, Sahlgrenska Universitetssjukhuset/ Ostra/Göteborg/Suède (5 aut.); Department of Cardiology, University of Barcelona/Barcelona/Espagne (6 aut.); Infectious Diseases Department, Hospital Universitari Vall d'Hebron/Barcelona/Espagne (7 aut.); Department of Infectious Disease, Hospital General Universitario Gregorio Maranon/Barcelona/Espagne (8 aut.); Department of Infectious Disease, Ospedali Riuniti/Bergamo/Italie (9 aut.); Cardiology Clinic, University Essen/Essen/Allemagne (10 aut.); Department of Infectious Disease, Medical Center Ljublijana/Ljublijana/Slovénie (11 aut.); Department of Infec tious Disease, Pontchaillou University/Rennes/France (12 aut.); Department of Cardiology, II Universita di Napoli/Naples/Italie (13 aut.); Cardiology Service, CHU Nancy-Brabois/Nancy/France (14 aut.); Laboratorio de Tecnicas No Invasivas, Hospital Clinico Pont Universidad Catolica de Chile/Santiago/Chili (15 aut.); Department of Cardiology, Institute de Cardiologia y Cirugia Cardiovascular, Fundacion Favaloro/Buenos Aires/Argentine (16 aut.); Diagnostic Medlab, Auckland City Hospital/Auckland/Nouvelle-Zélande (17 aut.)
DT :	Publication en série; Niveau analytique
SO :	JAMA, the journal of the American Medical Association; ISSN 0098-7484; Etats-Unis; Da. 2007; Vol. 297; No. 12; Pp. 1354-1361; Bibl. 41 ref.
LA :	Anglais
EA :	Context Prosthetic valve endocarditis (PVE) is associated with significant mortality and morbidity. The contemporary clinical profile and outcome of PVE are not well defined. Objectives To describe the prevalence, clinical characteristics, and outcome of PVE, with attention to health care-associated infection, and to determine prognostic factors associated with in-hospital mortality. Design, Setting, and Participants Prospective, observational cohort study conducted at 61 medical centers in 28 countries, including 556 patients with definite PVE as defined by Duke University diagnostic criteria who were enrolled in the International Collaboration on Endocarditis-Prospective Cohort Study from June 2000 to August 2005. Main Outcome Measure In-hospital mortality. Results Definite PVE was present in 556 (20.1 %) of 2670 patients with infective endocarditis. Staphylococcus aureus was the most common causative organism (128 patients [23.0%]), followed by coagulase-negative staphylococci (94 patients [16.9%]). Health care-associated PVE was present in 203 (36.5%) of the overall cohort. Seventy-one percent of health care-associated PVE occurred within the first year of valve implantation, and the majority of cases were diagnosed after the early (60-day) period. Surgery was performed in 272 (48.9%) patients during the index hospitalization. In-hospital death occurred in 127 (22.8%) patients and was predicted by older age, health care-associated infection (62/203 [30.5%]; adjusted odds ratio [OR], 1.62; 95% confidence interval [Cl], 1.08-2.44; P=.02), S aureus infection (44/128 [34.4%]; adjusted OR, 1.73; 95% Cl, 1.01-2.95; P=.05), and complications of PVE, including heart failure (60/183 [32.8%]; adjusted OR, 2.33; 95% Cl, 1.62-3.34; P<.001), stroke (34/101 [33.7%]; adjusted OR, 2.25; 95% Cl, 1.25-4.03; P=.007), intracardiac abscess (47/144 [32.6%]; adjusted OR, 1.86; 95% Cl, 1.10-3.15; P=.02), and persistent bacteremia (27/49 [55.1 %]; adjusted OR, 4.29; 95% Cl, 1.99-9.22; P<.001). Conclusions Prosthetic valve endocarditis accounts for a high percentage of all cases of infective endocarditis in many regions of the world. Staphylococcus aureus is now the leading cause of PVE. Health care-associated infection significantly influences the clinical characteristics and outcome of PVE. Complications of PVE strongly predict in-hospital mortality, which remains high despite prompt diagnosis and the frequent use of surgical intervention.
CC :	002B01; 002B25I; 002B12A04
FD :	Prothèse; Symptomatologie; Evolution; Endocardite; Pronostic; Valvule cardiaque; Médecine
FG :	Appareil circulatoire pathologie; Cardiopathie; Endocarde pathologie
ED :	Prosthesis; Symptomatology; Evolution; Endocarditis; Prognosis; Heart valve; Medicine
EG :	Cardiovascular disease; Heart disease; Endocardial disease
SD :	Prótesis; Sintomatología; Evolución; Endocarditis; Pronóstico; Válvula cardíaca; Medicina
LO :	INIST-5051.354000145706680070
ID :	07-0191068

Links to Exploration step

Pascal:07-0191068

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Contemporary clinical profile and outcome of prosthetic valve endocarditis</title>
<author><name sortKey="Wang, Andrew" sort="Wang, Andrew" uniqKey="Wang A" first="Andrew" last="Wang">Andrew Wang</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Medicine, Duke University Medical Center</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Athan, Eugene" sort="Athan, Eugene" uniqKey="Athan E" first="Eugene" last="Athan">Eugene Athan</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Infectious Disease, The Geelong Hospital at the University of Melbourne</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pappas, Paul A" sort="Pappas, Paul A" uniqKey="Pappas P" first="Paul A." last="Pappas">Paul A. Pappas</name>
<affiliation><inist:fA14 i1="03"><s1>Outcomes Research and Assessment Group, Duke Clinical Research Institute</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fowler, Vance G Jr" sort="Fowler, Vance G Jr" uniqKey="Fowler V" first="Vance G. Jr" last="Fowler">Vance G. Jr Fowler</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Medicine, Duke University Medical Center</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Olaison, Lars" sort="Olaison, Lars" uniqKey="Olaison L" first="Lars" last="Olaison">Lars Olaison</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Infectious Disease, Sahlgrenska Universitetssjukhuset/ Ostra</s1>
<s2>Göteborg</s2>
<s3>SWE</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pare, Carlos" sort="Pare, Carlos" uniqKey="Pare C" first="Carlos" last="Pare">Carlos Pare</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Cardiology, University of Barcelona</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Almirante, Benito" sort="Almirante, Benito" uniqKey="Almirante B" first="Benito" last="Almirante">Benito Almirante</name>
<affiliation><inist:fA14 i1="06"><s1>Infectious Diseases Department, Hospital Universitari Vall d'Hebron</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Munoz, Patricia" sort="Munoz, Patricia" uniqKey="Munoz P" first="Patricia" last="Munoz">Patricia Munoz</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Infectious Disease, Hospital General Universitario Gregorio Maranon</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rizzi, Marco" sort="Rizzi, Marco" uniqKey="Rizzi M" first="Marco" last="Rizzi">Marco Rizzi</name>
<affiliation><inist:fA14 i1="08"><s1>Department of Infectious Disease, Ospedali Riuniti</s1>
<s2>Bergamo</s2>
<s3>ITA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Naber, Christoph" sort="Naber, Christoph" uniqKey="Naber C" first="Christoph" last="Naber">Christoph Naber</name>
<affiliation><inist:fA14 i1="09"><s1>Cardiology Clinic, University Essen</s1>
<s2>Essen</s2>
<s3>DEU</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Logar, Mateja" sort="Logar, Mateja" uniqKey="Logar M" first="Mateja" last="Logar">Mateja Logar</name>
<affiliation><inist:fA14 i1="10"><s1>Department of Infectious Disease, Medical Center Ljublijana</s1>
<s2>Ljublijana</s2>
<s3>SVN</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tattevin, Pierre" sort="Tattevin, Pierre" uniqKey="Tattevin P" first="Pierre" last="Tattevin">Pierre Tattevin</name>
<affiliation><inist:fA14 i1="11"><s1>Department of Infec tious Disease, Pontchaillou University</s1>
<s2>Rennes</s2>
<s3>FRA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Iarussi, Diana L" sort="Iarussi, Diana L" uniqKey="Iarussi D" first="Diana L." last="Iarussi">Diana L. Iarussi</name>
<affiliation><inist:fA14 i1="12"><s1>Department of Cardiology, II Universita di Napoli</s1>
<s2>Naples</s2>
<s3>ITA</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Selton Suty, Christine" sort="Selton Suty, Christine" uniqKey="Selton Suty C" first="Christine" last="Selton-Suty">Christine Selton-Suty</name>
<affiliation><inist:fA14 i1="13"><s1>Cardiology Service, CHU Nancy-Brabois</s1>
<s2>Nancy</s2>
<s3>FRA</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Braun Jones, Sandra" sort="Braun Jones, Sandra" uniqKey="Braun Jones S" first="Sandra" last="Braun Jones">Sandra Braun Jones</name>
<affiliation><inist:fA14 i1="14"><s1>Laboratorio de Tecnicas No Invasivas, Hospital Clinico Pont Universidad Catolica de Chile</s1>
<s2>Santiago</s2>
<s3>CHL</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Casabe, Jose" sort="Casabe, Jose" uniqKey="Casabe J" first="José" last="Casabe">José Casabe</name>
<affiliation><inist:fA14 i1="15"><s1>Department of Cardiology, Institute de Cardiologia y Cirugia Cardiovascular, Fundacion Favaloro</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Morris, Arthur" sort="Morris, Arthur" uniqKey="Morris A" first="Arthur" last="Morris">Arthur Morris</name>
<affiliation><inist:fA14 i1="16"><s1>Diagnostic Medlab, Auckland City Hospital</s1>
<s2>Auckland</s2>
<s3>NZL</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Corey, Ralph" sort="Corey, Ralph" uniqKey="Corey R" first="Ralph" last="Corey">Ralph Corey</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Medicine, Duke University Medical Center</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cabell, Christopher H" sort="Cabell, Christopher H" uniqKey="Cabell C" first="Christopher H." last="Cabell">Christopher H. Cabell</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Medicine, Duke University Medical Center</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">07-0191068</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 07-0191068 INIST</idno>
<idno type="RBID">Pascal:07-0191068</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003D00</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Contemporary clinical profile and outcome of prosthetic valve endocarditis</title>
<author><name sortKey="Wang, Andrew" sort="Wang, Andrew" uniqKey="Wang A" first="Andrew" last="Wang">Andrew Wang</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Medicine, Duke University Medical Center</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Athan, Eugene" sort="Athan, Eugene" uniqKey="Athan E" first="Eugene" last="Athan">Eugene Athan</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Infectious Disease, The Geelong Hospital at the University of Melbourne</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pappas, Paul A" sort="Pappas, Paul A" uniqKey="Pappas P" first="Paul A." last="Pappas">Paul A. Pappas</name>
<affiliation><inist:fA14 i1="03"><s1>Outcomes Research and Assessment Group, Duke Clinical Research Institute</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fowler, Vance G Jr" sort="Fowler, Vance G Jr" uniqKey="Fowler V" first="Vance G. Jr" last="Fowler">Vance G. Jr Fowler</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Medicine, Duke University Medical Center</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Olaison, Lars" sort="Olaison, Lars" uniqKey="Olaison L" first="Lars" last="Olaison">Lars Olaison</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Infectious Disease, Sahlgrenska Universitetssjukhuset/ Ostra</s1>
<s2>Göteborg</s2>
<s3>SWE</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pare, Carlos" sort="Pare, Carlos" uniqKey="Pare C" first="Carlos" last="Pare">Carlos Pare</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Cardiology, University of Barcelona</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Almirante, Benito" sort="Almirante, Benito" uniqKey="Almirante B" first="Benito" last="Almirante">Benito Almirante</name>
<affiliation><inist:fA14 i1="06"><s1>Infectious Diseases Department, Hospital Universitari Vall d'Hebron</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Munoz, Patricia" sort="Munoz, Patricia" uniqKey="Munoz P" first="Patricia" last="Munoz">Patricia Munoz</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Infectious Disease, Hospital General Universitario Gregorio Maranon</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rizzi, Marco" sort="Rizzi, Marco" uniqKey="Rizzi M" first="Marco" last="Rizzi">Marco Rizzi</name>
<affiliation><inist:fA14 i1="08"><s1>Department of Infectious Disease, Ospedali Riuniti</s1>
<s2>Bergamo</s2>
<s3>ITA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Naber, Christoph" sort="Naber, Christoph" uniqKey="Naber C" first="Christoph" last="Naber">Christoph Naber</name>
<affiliation><inist:fA14 i1="09"><s1>Cardiology Clinic, University Essen</s1>
<s2>Essen</s2>
<s3>DEU</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Logar, Mateja" sort="Logar, Mateja" uniqKey="Logar M" first="Mateja" last="Logar">Mateja Logar</name>
<affiliation><inist:fA14 i1="10"><s1>Department of Infectious Disease, Medical Center Ljublijana</s1>
<s2>Ljublijana</s2>
<s3>SVN</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tattevin, Pierre" sort="Tattevin, Pierre" uniqKey="Tattevin P" first="Pierre" last="Tattevin">Pierre Tattevin</name>
<affiliation><inist:fA14 i1="11"><s1>Department of Infec tious Disease, Pontchaillou University</s1>
<s2>Rennes</s2>
<s3>FRA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Iarussi, Diana L" sort="Iarussi, Diana L" uniqKey="Iarussi D" first="Diana L." last="Iarussi">Diana L. Iarussi</name>
<affiliation><inist:fA14 i1="12"><s1>Department of Cardiology, II Universita di Napoli</s1>
<s2>Naples</s2>
<s3>ITA</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Selton Suty, Christine" sort="Selton Suty, Christine" uniqKey="Selton Suty C" first="Christine" last="Selton-Suty">Christine Selton-Suty</name>
<affiliation><inist:fA14 i1="13"><s1>Cardiology Service, CHU Nancy-Brabois</s1>
<s2>Nancy</s2>
<s3>FRA</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Braun Jones, Sandra" sort="Braun Jones, Sandra" uniqKey="Braun Jones S" first="Sandra" last="Braun Jones">Sandra Braun Jones</name>
<affiliation><inist:fA14 i1="14"><s1>Laboratorio de Tecnicas No Invasivas, Hospital Clinico Pont Universidad Catolica de Chile</s1>
<s2>Santiago</s2>
<s3>CHL</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Casabe, Jose" sort="Casabe, Jose" uniqKey="Casabe J" first="José" last="Casabe">José Casabe</name>
<affiliation><inist:fA14 i1="15"><s1>Department of Cardiology, Institute de Cardiologia y Cirugia Cardiovascular, Fundacion Favaloro</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Morris, Arthur" sort="Morris, Arthur" uniqKey="Morris A" first="Arthur" last="Morris">Arthur Morris</name>
<affiliation><inist:fA14 i1="16"><s1>Diagnostic Medlab, Auckland City Hospital</s1>
<s2>Auckland</s2>
<s3>NZL</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Corey, Ralph" sort="Corey, Ralph" uniqKey="Corey R" first="Ralph" last="Corey">Ralph Corey</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Medicine, Duke University Medical Center</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cabell, Christopher H" sort="Cabell, Christopher H" uniqKey="Cabell C" first="Christopher H." last="Cabell">Christopher H. Cabell</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Medicine, Duke University Medical Center</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">JAMA, the journal of the American Medical Association</title>
<title level="j" type="abbreviated">JAMA j. Am. Med. Assoc.</title>
<idno type="ISSN">0098-7484</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">JAMA, the journal of the American Medical Association</title>
<title level="j" type="abbreviated">JAMA j. Am. Med. Assoc.</title>
<idno type="ISSN">0098-7484</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Endocarditis</term>
<term>Evolution</term>
<term>Heart valve</term>
<term>Medicine</term>
<term>Prognosis</term>
<term>Prosthesis</term>
<term>Symptomatology</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Prothèse</term>
<term>Symptomatologie</term>
<term>Evolution</term>
<term>Endocardite</term>
<term>Pronostic</term>
<term>Valvule cardiaque</term>
<term>Médecine</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Context Prosthetic valve endocarditis (PVE) is associated with significant mortality and morbidity. The contemporary clinical profile and outcome of PVE are not well defined. Objectives To describe the prevalence, clinical characteristics, and outcome of PVE, with attention to health care-associated infection, and to determine prognostic factors associated with in-hospital mortality. Design, Setting, and Participants Prospective, observational cohort study conducted at 61 medical centers in 28 countries, including 556 patients with definite PVE as defined by Duke University diagnostic criteria who were enrolled in the International Collaboration on Endocarditis-Prospective Cohort Study from June 2000 to August 2005. Main Outcome Measure In-hospital mortality. Results Definite PVE was present in 556 (20.1 %) of 2670 patients with infective endocarditis. Staphylococcus aureus was the most common causative organism (128 patients [23.0%]), followed by coagulase-negative staphylococci (94 patients [16.9%]). Health care-associated PVE was present in 203 (36.5%) of the overall cohort. Seventy-one percent of health care-associated PVE occurred within the first year of valve implantation, and the majority of cases were diagnosed after the early (60-day) period. Surgery was performed in 272 (48.9%) patients during the index hospitalization. In-hospital death occurred in 127 (22.8%) patients and was predicted by older age, health care-associated infection (62/203 [30.5%]; adjusted odds ratio [OR], 1.62; 95% confidence interval [Cl], 1.08-2.44; P=.02), S aureus infection (44/128 [34.4%]; adjusted OR, 1.73; 95% Cl, 1.01-2.95; P=.05), and complications of PVE, including heart failure (60/183 [32.8%]; adjusted OR, 2.33; 95% Cl, 1.62-3.34; P<.001), stroke (34/101 [33.7%]; adjusted OR, 2.25; 95% Cl, 1.25-4.03; P=.007), intracardiac abscess (47/144 [32.6%]; adjusted OR, 1.86; 95% Cl, 1.10-3.15; P=.02), and persistent bacteremia (27/49 [55.1 %]; adjusted OR, 4.29; 95% Cl, 1.99-9.22; P<.001). Conclusions Prosthetic valve endocarditis accounts for a high percentage of all cases of infective endocarditis in many regions of the world. Staphylococcus aureus is now the leading cause of PVE. Health care-associated infection significantly influences the clinical characteristics and outcome of PVE. Complications of PVE strongly predict in-hospital mortality, which remains high despite prompt diagnosis and the frequent use of surgical intervention.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0098-7484</s0>
</fA01>
<fA03 i2="1"><s0>JAMA j. Am. Med. Assoc.</s0>
</fA03>
<fA05><s2>297</s2>
</fA05>
<fA06><s2>12</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Contemporary clinical profile and outcome of prosthetic valve endocarditis</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>WANG (Andrew)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>ATHAN (Eugene)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>PAPPAS (Paul A.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>FOWLER (Vance G. JR)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>OLAISON (Lars)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>PARE (Carlos)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>ALMIRANTE (Benito)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>MUNOZ (Patricia)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>RIZZI (Marco)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>NABER (Christoph)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>LOGAR (Mateja)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>TATTEVIN (Pierre)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>IARUSSI (Diana L.)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>SELTON-SUTY (Christine)</s1>
</fA11>
<fA11 i1="15" i2="1"><s1>BRAUN JONES (Sandra)</s1>
</fA11>
<fA11 i1="16" i2="1"><s1>CASABE (José)</s1>
</fA11>
<fA11 i1="17" i2="1"><s1>MORRIS (Arthur)</s1>
</fA11>
<fA11 i1="18" i2="1"><s1>COREY (Ralph)</s1>
</fA11>
<fA11 i1="19" i2="1"><s1>CABELL (Christopher H.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Medicine, Duke University Medical Center</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Infectious Disease, The Geelong Hospital at the University of Melbourne</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Outcomes Research and Assessment Group, Duke Clinical Research Institute</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Infectious Disease, Sahlgrenska Universitetssjukhuset/ Ostra</s1>
<s2>Göteborg</s2>
<s3>SWE</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Cardiology, University of Barcelona</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Infectious Diseases Department, Hospital Universitari Vall d'Hebron</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Infectious Disease, Hospital General Universitario Gregorio Maranon</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Department of Infectious Disease, Ospedali Riuniti</s1>
<s2>Bergamo</s2>
<s3>ITA</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Cardiology Clinic, University Essen</s1>
<s2>Essen</s2>
<s3>DEU</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Department of Infectious Disease, Medical Center Ljublijana</s1>
<s2>Ljublijana</s2>
<s3>SVN</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>Department of Infec tious Disease, Pontchaillou University</s1>
<s2>Rennes</s2>
<s3>FRA</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="12"><s1>Department of Cardiology, II Universita di Napoli</s1>
<s2>Naples</s2>
<s3>ITA</s3>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="13"><s1>Cardiology Service, CHU Nancy-Brabois</s1>
<s2>Nancy</s2>
<s3>FRA</s3>
<sZ>14 aut.</sZ>
</fA14>
<fA14 i1="14"><s1>Laboratorio de Tecnicas No Invasivas, Hospital Clinico Pont Universidad Catolica de Chile</s1>
<s2>Santiago</s2>
<s3>CHL</s3>
<sZ>15 aut.</sZ>
</fA14>
<fA14 i1="15"><s1>Department of Cardiology, Institute de Cardiologia y Cirugia Cardiovascular, Fundacion Favaloro</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>16 aut.</sZ>
</fA14>
<fA14 i1="16"><s1>Diagnostic Medlab, Auckland City Hospital</s1>
<s2>Auckland</s2>
<s3>NZL</s3>
<sZ>17 aut.</sZ>
</fA14>
<fA20><s1>1354-1361</s1>
</fA20>
<fA21><s1>2007</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>5051</s2>
<s5>354000145706680070</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2007 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>41 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>07-0191068</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>JAMA, the journal of the American Medical Association</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Context Prosthetic valve endocarditis (PVE) is associated with significant mortality and morbidity. The contemporary clinical profile and outcome of PVE are not well defined. Objectives To describe the prevalence, clinical characteristics, and outcome of PVE, with attention to health care-associated infection, and to determine prognostic factors associated with in-hospital mortality. Design, Setting, and Participants Prospective, observational cohort study conducted at 61 medical centers in 28 countries, including 556 patients with definite PVE as defined by Duke University diagnostic criteria who were enrolled in the International Collaboration on Endocarditis-Prospective Cohort Study from June 2000 to August 2005. Main Outcome Measure In-hospital mortality. Results Definite PVE was present in 556 (20.1 %) of 2670 patients with infective endocarditis. Staphylococcus aureus was the most common causative organism (128 patients [23.0%]), followed by coagulase-negative staphylococci (94 patients [16.9%]). Health care-associated PVE was present in 203 (36.5%) of the overall cohort. Seventy-one percent of health care-associated PVE occurred within the first year of valve implantation, and the majority of cases were diagnosed after the early (60-day) period. Surgery was performed in 272 (48.9%) patients during the index hospitalization. In-hospital death occurred in 127 (22.8%) patients and was predicted by older age, health care-associated infection (62/203 [30.5%]; adjusted odds ratio [OR], 1.62; 95% confidence interval [Cl], 1.08-2.44; P=.02), S aureus infection (44/128 [34.4%]; adjusted OR, 1.73; 95% Cl, 1.01-2.95; P=.05), and complications of PVE, including heart failure (60/183 [32.8%]; adjusted OR, 2.33; 95% Cl, 1.62-3.34; P<.001), stroke (34/101 [33.7%]; adjusted OR, 2.25; 95% Cl, 1.25-4.03; P=.007), intracardiac abscess (47/144 [32.6%]; adjusted OR, 1.86; 95% Cl, 1.10-3.15; P=.02), and persistent bacteremia (27/49 [55.1 %]; adjusted OR, 4.29; 95% Cl, 1.99-9.22; P<.001). Conclusions Prosthetic valve endocarditis accounts for a high percentage of all cases of infective endocarditis in many regions of the world. Staphylococcus aureus is now the leading cause of PVE. Health care-associated infection significantly influences the clinical characteristics and outcome of PVE. Complications of PVE strongly predict in-hospital mortality, which remains high despite prompt diagnosis and the frequent use of surgical intervention.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B01</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B25I</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B12A04</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Prothèse</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Prosthesis</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Prótesis</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Symptomatologie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Symptomatology</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sintomatología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Evolution</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Evolution</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Evolución</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Endocardite</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Endocarditis</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Endocarditis</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Pronostic</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Prognosis</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Pronóstico</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Valvule cardiaque</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Heart valve</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Válvula cardíaca</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Médecine</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Medicine</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Medicina</s0>
<s5>08</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Appareil circulatoire pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cardiovascular disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Cardiopathie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Heart disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Cardiopatía</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Endocarde pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Endocardial disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Endocardio patología</s0>
<s5>39</s5>
</fC07>
<fN21><s1>128</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 07-0191068 INIST</NO>
<ET>Contemporary clinical profile and outcome of prosthetic valve endocarditis</ET>
<AU>WANG (Andrew); ATHAN (Eugene); PAPPAS (Paul A.); FOWLER (Vance G. JR); OLAISON (Lars); PARE (Carlos); ALMIRANTE (Benito); MUNOZ (Patricia); RIZZI (Marco); NABER (Christoph); LOGAR (Mateja); TATTEVIN (Pierre); IARUSSI (Diana L.); SELTON-SUTY (Christine); BRAUN JONES (Sandra); CASABE (José); MORRIS (Arthur); COREY (Ralph); CABELL (Christopher H.)</AU>
<AF>Department of Medicine, Duke University Medical Center/Durham, NC/Etats-Unis (1 aut., 4 aut., 18 aut., 19 aut.); Department of Infectious Disease, The Geelong Hospital at the University of Melbourne/Melbourne/Australie (2 aut.); Outcomes Research and Assessment Group, Duke Clinical Research Institute/Durham, NC/Etats-Unis (3 aut.); Department of Infectious Disease, Sahlgrenska Universitetssjukhuset/ Ostra/Göteborg/Suède (5 aut.); Department of Cardiology, University of Barcelona/Barcelona/Espagne (6 aut.); Infectious Diseases Department, Hospital Universitari Vall d'Hebron/Barcelona/Espagne (7 aut.); Department of Infectious Disease, Hospital General Universitario Gregorio Maranon/Barcelona/Espagne (8 aut.); Department of Infectious Disease, Ospedali Riuniti/Bergamo/Italie (9 aut.); Cardiology Clinic, University Essen/Essen/Allemagne (10 aut.); Department of Infectious Disease, Medical Center Ljublijana/Ljublijana/Slovénie (11 aut.); Department of Infec tious Disease, Pontchaillou University/Rennes/France (12 aut.); Department of Cardiology, II Universita di Napoli/Naples/Italie (13 aut.); Cardiology Service, CHU Nancy-Brabois/Nancy/France (14 aut.); Laboratorio de Tecnicas No Invasivas, Hospital Clinico Pont Universidad Catolica de Chile/Santiago/Chili (15 aut.); Department of Cardiology, Institute de Cardiologia y Cirugia Cardiovascular, Fundacion Favaloro/Buenos Aires/Argentine (16 aut.); Diagnostic Medlab, Auckland City Hospital/Auckland/Nouvelle-Zélande (17 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>JAMA, the journal of the American Medical Association; ISSN 0098-7484; Etats-Unis; Da. 2007; Vol. 297; No. 12; Pp. 1354-1361; Bibl. 41 ref.</SO>
<LA>Anglais</LA>
<EA>Context Prosthetic valve endocarditis (PVE) is associated with significant mortality and morbidity. The contemporary clinical profile and outcome of PVE are not well defined. Objectives To describe the prevalence, clinical characteristics, and outcome of PVE, with attention to health care-associated infection, and to determine prognostic factors associated with in-hospital mortality. Design, Setting, and Participants Prospective, observational cohort study conducted at 61 medical centers in 28 countries, including 556 patients with definite PVE as defined by Duke University diagnostic criteria who were enrolled in the International Collaboration on Endocarditis-Prospective Cohort Study from June 2000 to August 2005. Main Outcome Measure In-hospital mortality. Results Definite PVE was present in 556 (20.1 %) of 2670 patients with infective endocarditis. Staphylococcus aureus was the most common causative organism (128 patients [23.0%]), followed by coagulase-negative staphylococci (94 patients [16.9%]). Health care-associated PVE was present in 203 (36.5%) of the overall cohort. Seventy-one percent of health care-associated PVE occurred within the first year of valve implantation, and the majority of cases were diagnosed after the early (60-day) period. Surgery was performed in 272 (48.9%) patients during the index hospitalization. In-hospital death occurred in 127 (22.8%) patients and was predicted by older age, health care-associated infection (62/203 [30.5%]; adjusted odds ratio [OR], 1.62; 95% confidence interval [Cl], 1.08-2.44; P=.02), S aureus infection (44/128 [34.4%]; adjusted OR, 1.73; 95% Cl, 1.01-2.95; P=.05), and complications of PVE, including heart failure (60/183 [32.8%]; adjusted OR, 2.33; 95% Cl, 1.62-3.34; P<.001), stroke (34/101 [33.7%]; adjusted OR, 2.25; 95% Cl, 1.25-4.03; P=.007), intracardiac abscess (47/144 [32.6%]; adjusted OR, 1.86; 95% Cl, 1.10-3.15; P=.02), and persistent bacteremia (27/49 [55.1 %]; adjusted OR, 4.29; 95% Cl, 1.99-9.22; P<.001). Conclusions Prosthetic valve endocarditis accounts for a high percentage of all cases of infective endocarditis in many regions of the world. Staphylococcus aureus is now the leading cause of PVE. Health care-associated infection significantly influences the clinical characteristics and outcome of PVE. Complications of PVE strongly predict in-hospital mortality, which remains high despite prompt diagnosis and the frequent use of surgical intervention.</EA>
<CC>002B01; 002B25I; 002B12A04</CC>
<FD>Prothèse; Symptomatologie; Evolution; Endocardite; Pronostic; Valvule cardiaque; Médecine</FD>
<FG>Appareil circulatoire pathologie; Cardiopathie; Endocarde pathologie</FG>
<ED>Prosthesis; Symptomatology; Evolution; Endocarditis; Prognosis; Heart valve; Medicine</ED>
<EG>Cardiovascular disease; Heart disease; Endocardial disease</EG>
<SD>Prótesis; Sintomatología; Evolución; Endocarditis; Pronóstico; Válvula cardíaca; Medicina</SD>
<LO>INIST-5051.354000145706680070</LO>
<ID>07-0191068</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003D00 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 003D00 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:07-0191068
   |texte=   Contemporary clinical profile and outcome of prosthetic valve endocarditis
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Contemporary clinical profile and outcome of prosthetic valve endocarditis

Contemporary clinical profile and outcome of prosthetic valve endocarditis

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri